Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

PROCEPT BioRobotics (PRCT) Enterprise Value (2021 - 2026)

PROCEPT BioRobotics has reported Enterprise Value over the past 7 years, most recently at -$245.6 million for Q1 2026.

  • Quarterly Enterprise Value rose 22.32% to -$245.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$245.6 million through Mar 2026, up 22.32% year-over-year, with the annual reading at -$286.5 million for FY2025, 14.15% up from the prior year.
  • Enterprise Value was -$245.6 million for Q1 2026 at PROCEPT BioRobotics, up from -$286.5 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$150.5 million in Q2 2023 and troughed at -$333.7 million in Q4 2024.
  • The 5-year median for Enterprise Value is -$257.2 million (2023), against an average of -$254.0 million.
  • Year-over-year, Enterprise Value tumbled 230.11% in 2022 and then skyrocketed 44.23% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$222.6 million in 2022, then fell by 15.53% to -$257.2 million in 2023, then decreased by 29.74% to -$333.7 million in 2024, then grew by 14.15% to -$286.5 million in 2025, then rose by 14.26% to -$245.6 million in 2026.
  • Per Business Quant, the three most recent readings for PRCT's Enterprise Value are -$245.6 million (Q1 2026), -$286.5 million (Q4 2025), and -$294.3 million (Q3 2025).